At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 534 enrolled
Drug / intervention
Dexpramipexole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma
In Brief
A Phase 2 clinical trial evaluating Dexpramipexole and Placebo for Eosinophilic Asthma and Asthma. Completed, enrolled 534 participants across 36 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Asthma, Asthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartAug 2019
Primary CompletionDec 2020
Study CompletionMar 2021
TodayJul 2026
First PostedAug 6, 2019
Enrollment StartAug 15, 2019
Primary CompletionDec 3, 2020
Study CompletionMar 2, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.9 years ago
Interventions
Dexpramipexoledrug
dexpramipexole twice daily oral dosing for up to 12 weeks
Placebodrug
placebo twice daily oral dosing for up to 12 weeks